Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Colorectal Neoplasms 56Ovarian Neoplasms 35Carcinoma, Hepatocellular 35Neoplasms 25Fallopian Tube Neoplasms 20Carcinoma, Non-Small-Cell Lung 19Endometrial Neoplasms 13Glioblastoma 11Breast Neoplasms 11Brain Neoplasms 11Neoplasm Metastasis 9Colonic Neoplasms 9Lung Neoplasms 8Uterine Cervical Neoplasms 7Liver Neoplasms 7Rectal Neoplasms 6Glioma 6Biliary Tract Neoplasms 6Stomach Neoplasms 5Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Gastrointestinal Neoplasms 4Digestive System Neoplasms 4Carcinoma, Ovarian Epithelial 4Small Cell Lung Carcinoma 3Sarcoma 3Recurrence 3Peritoneal Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Neoplasms 3

Interventions

relacorilant 1Bevacizumab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Diseases × Bevacizumab × 90 days × Clear all
NCT06906341 2026-04-14

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Corcept Therapeutics

Phase 2 Recruiting
270 enrolled
Gynecologic

Fallopian Tube Diseases, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Diseases, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡